Thermo Unveils New Data Acquisition System
ePT--the Electronic Newsletter of Pharmaceutical Technology
Thermo Electron (Waltham, MA, www.thermo.com) debuted the "LCQUAN 2.5" data-acquisition system at the AAPS Annual Meeting and Exposition on Monday. The new system expands the software offerings for the company's "Finnigan TSQ Quantum" series of triple quadrupole mass spectrometers.
Thermo Electron (Waltham, MA, www.thermo.com) debuted the "LCQUAN 2.5" data-acquisition system at the AAPS Annual Meeting and Exposition on Monday. The new system expands the software offerings for the company's "Finnigan TSQ Quantum" series of triple quadrupole mass spectrometers.
The LCQUAN 2.5 quantitative software package is 21 CFR Part 11 compliant and includes new features such as remote disk support; a workbook-style,centralized file location; and a digital, secure, bidirectional interface with Thermo's "Watson" laboratory management system.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
